Orbis Medicines launches with €26 million seed financing led by Novo Holdings and Forbion to transform macrocycle drug development through next-generation orally dosable ‘nCycles’.

Feb 29, 2024•almost 2 years ago

Amount Raised

€26 Million

Round Type

seed

CopenhagenBiotechnology

Investors

ForbionNovo Holdings

Description

Orbis Medicines announces its launch with a €26 million seed financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion. The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’.

Company Information

Company

Orbis Medicines

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Orbis Medicines is a biotechnology company focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. Orbis’ nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver oral macrocycle drug candidates – nCycles – suitable for both intra- and extracellular targets. Orbis’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets challenging for established modalities.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends